Low-temperature crystal structures of Tetrakis-mu-3,5-diisopropylsalicylatobis-dimethylformamidodicopper(II) and Tetrakis-mu-3,5-diisopropylsalicylatobis-diethyletheratodicopper(II) and their role in modulating polymorphonuclear leukocyte activity in overcoming seizures
G. Morgant et al., Low-temperature crystal structures of Tetrakis-mu-3,5-diisopropylsalicylatobis-dimethylformamidodicopper(II) and Tetrakis-mu-3,5-diisopropylsalicylatobis-diethyletheratodicopper(II) and their role in modulating polymorphonuclear leukocyte activity in overcoming seizures, J INORG BIO, 81(1-2), 2000, pp. 11-22
Two binuclear copper(II) complexes of 3,5-diisopropylsalicylic acid were ch
aracterized by single crystal X-ray diffraction methods and examined for an
ti-inflammatory activity using activated polymorphonuclear leukocytes and f
or anticonvulsant activities using electroshock and metrazol models of seiz
ures. These complexes were crystallized from dimethylformamide (DMF) or die
thylether. Tetrakis-mu-3,5-diisopropylsalicylatobis-dimethylformamidodicopp
er(II) [Cu(II)(2)(3,5-DIPS)(4)(DMF)(2)] I is in space group P (s) over bar;
a=10.393 (2), b=11.258 (2), c=12,734 (2) Angstrom, alpha=96.64 (2), beta=9
2.95 (2), gamma=94.90 (2)degrees; V=1471.7 (4) Angstrom(3); Z=1. Tetrakis-m
u-3,5-diisopropylsalicylatobis-etheratodicopper(II) [Cu(II)(2)(3,5-DIPS)(4)
(ether)(2)] II is in space group P (1) over bar; a=10.409 (3), b=11.901 (4)
, c=12.687 (6) Angstrom, alpha = 91.12 (5), beta = 90.84 (5), gamma = 100.9
0 (4)degrees; V= 1542 (1) Angstrom(3); Z= 1. The structure of I was determi
ned at 140 K from 4361 unique reflections (1 > 2 sigma(1)) and refined on F
-2 to R1= 0.04 and wR2=0.09. The structure of II was determined at 180 K fr
om 4605 unique reflections (1 > 2 sigma(1)) and refined on F-2 to R1 = 0.05
and wR2 = 0.13. Each compound is a crystallographically centrosymmetric bi
nuclear complex with Cu atoms bridged by four 3,5-diisopropylsalicylate lig
ands related by a symmetry center [Cu-Cu-l: 2.6139 (9) Angstrom in I and 2.
613 (1) in II]. The four nearest O atoms around each Cu atom form a nearly
rectangular planar arrangement with the square pyramidal coordination compl
eted by the dimethylformamide (or diethylether) oxygen atom occupying an ap
ical position, at a distance of 2.129 (2) Angstrom in I and 2.230 (3) Angst
rom in II. Each Cu atom is displaced towards the DMF (or diethylether) liga
nd, by 0.189 Angstrom in I and 0.184 Angstrom in II, from the plane of the
four O atoms. The crystal structures of I and II are essentially similar to
each other, except for the DMF or diethylether accommodation. Many disorde
r phenomena were found in the crystal structure of I. Copper(II),(3,5-DIPS)
(4)(DMF)(2) inhibited polymorphonuclear leukocyte (PMNL) oxidative metaboli
sm in vitro. This effect was concentration related and significant for conc
entrations higher than 10 mu g or 0.68 nmol/ml. Copper(II)(2)(3,S-DIPS)(4)(
DMF)(2) was more active than the parent ligand, 3,5-DIPS, as has been demon
strated with copper complexes of other non-steroidal anti-inflammatory drug
s. The DMF and diethylether ternary complexes of Cu(II)(2)(3,5-DIPS)(4) wer
e found to have anticonvulsant activity in the maximal electroshock model o
f grand mal epilepsy in doses ranging from 26 to 258 mu mol/kg of body mass
following intraperitoneal, subcutaneous, or oral treatment. The DMF ternar
y complex was also found to be effective in the subcutaneous injection of m
etrazol model of petit mal epilepsy. We conclude that both ternary copper c
omplexes are lipophilic and bioavailable, capable of facilitating the infla
mmatory response to brain injury and causing the subsidence of this respons
e in bringing about remission of these disease states. (C) 2000 Elsevier Sc
ience S.A. All rights reserved.